{"id":2365,"date":"2024-05-03T13:04:36","date_gmt":"2024-05-03T13:04:36","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2365"},"modified":"2024-05-03T13:04:38","modified_gmt":"2024-05-03T13:04:38","slug":"amgens-obesity-drug-excites-investors-as-shares-surge","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/05\/03\/amgens-obesity-drug-excites-investors-as-shares-surge\/","title":{"rendered":"Amgen&#8217;s Obesity Drug Excites Investors as Shares Surge"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Positive Early Results Propel Amgen to Compete in Lucrative Weight-Loss Market<\/h4>\n\n\n\n<p>Amgen (AMGN) experienced a significant surge in its shares following encouraging remarks from its CEO, Robert Bradway, regarding early results from the study of the company&#8217;s experimental obesity drug, MariTide. Bradway expressed confidence in MariTide&#8217;s potential to address crucial unmet medical needs in the field of obesity treatment, triggering a notable uptick in investor optimism.<\/p>\n\n\n\n<p>The California-based biopharmaceutical company&#8217;s stock soared by as much as 15% in pre-market trading, positioning it for its most significant increase since July 2009. Amgen is now emerging as a formidable competitor to industry giants like Eli Lilly &amp; Co. and Novo Nordisk A\/S in the weight-loss market. This move comes amidst a surge in demand for anti-obesity drugs, with projected annual sales expected to reach $80 billion by 2030.<\/p>\n\n\n\n<p>Analysts are optimistic about MariTide&#8217;s potential, with William Blair analyst Matt Phipps highlighting its multi-blockbuster prospects. The drug&#8217;s differentiated profile, coupled with Amgen&#8217;s expertise, has bolstered confidence in its development.<\/p>\n\n\n\n<p>Meanwhile, Denmark&#8217;s Novo Nordisk saw a decline in its shares following the Amgen CEO&#8217;s remarks, underlining the shifting dynamics in the competitive landscape. Amgen&#8217;s MariTide, with its novel approach and promising early-stage results, has ignited enthusiasm among investors and positioned the company for a significant role in the evolving obesity treatment market.<\/p>\n\n\n\n<p>You might like this article:<mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\"> <a href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/02\/moderna-reports-narrower-loss-amid-decline-in-covid-vaccine-sales\/\">Moderna Reports Narrower Loss Amid Decline in Covid Vaccine Sales<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Positive Early Results Propel Amgen to Compete in Lucrative Weight-Loss Market Amgen (AMGN) experienced a significant surge in its shares following encouraging remarks from its CEO, Robert Bradway, regarding early results from the study of the company&#8217;s experimental obesity drug, MariTide. Bradway expressed confidence in MariTide&#8217;s potential to address crucial unmet medical needs in the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[361,309],"tags":[],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2365"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2365"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2365\/revisions"}],"predecessor-version":[{"id":2366,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2365\/revisions\/2366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1429"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2365"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}